- Home
- SOPH vs TCRX Comparison
SOPH vs TCRX Comparison
Compare SOPH & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOPH | TCRX |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.4M | 64.1M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SOPH | TCRX |
|---|---|---|
| Price | $4.60 | $1.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $7.00 | ★ $8.50 |
| AVG Volume (30 Days) | 84.8K | ★ 745.0K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $73,297,000.00 | $8,423,000.00 |
| Revenue This Year | $18.32 | $286.83 |
| Revenue Next Year | $15.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.66 | N/A |
| 52 Week Low | $2.58 | $0.88 |
| 52 Week High | $5.30 | $3.43 |
Technical Indicators
Market Signals| Indicator | SOPH | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | 49.34 |
| Support Level | $4.60 | $0.88 |
| Resistance Level | $4.84 | $0.96 |
| Average True Range (ATR) | 0.23 | 0.08 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 17.51 | 77.81 |
Price Performance
Historical ComparisonAbout SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.